Screener
Royalty Pharma RPRX TEV-408 — Unfunded Commitments
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept rprx:ResearchAndDevelopmentUnfundedCommitments.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
| Product Candidates | Counterparties | Total Commitments | Funding Timing | Unfunded Commitments |
|---|---|---|---|---|
| JNJ‑4804 | Johnson & Johnson | $500,000 | Eight fixed quarterly payments commencing in the second quarter of 2026 | $437,500 |
| TEV-’408(1) | Teva Pharmaceuticals | 75,000 | Variable quarterly payments commencing in second quarter of 2026 | 65,149 |
| Litifilimab | Biogen | 250,000 | Six fixed quarterly payments commencing in first quarter of 2025 | — |
| Total | $825,000 | $502,649 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Royalty Pharma's TEV-408 — unfunded commitments?
- Royalty Pharma (RPRX) reported TEV-408 — unfunded commitments of $65.15M in Q2 2026.
- What does TEV-408 — unfunded commitments mean?
- This metric measures the portion of total contractual royalty acquisition obligations that has not yet been disbursed to partners. It represents the remaining capital the firm is obligated to pay out as specific milestones or development targets are achieved. Tracking this provides visibility into near-term liquidity requirements and the timing of future cash outflows.
Ask your AI about Royalty Pharma's tev-408 — unfunded commitments.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude